Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ: NVCR )

30.47 -1.43 (-4.48%)
Streaming Delayed Price Updated: 2:30 PM EST, Dec 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
17 18 Next >
Dow Drops 50 Points; J.M. Smucker Earnings Top Views
U.S. stocks traded lower this morning, with Dow Jones dropping around 50 points on Monday. The Dow traded down 0.16% to 33,509.87 while the NASDAQ fell 0.19% to 13,203.91. The S&P 500, also fell,... 
Via Benzinga
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
From Zai Lab Limited
Via GlobeNewswire
LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
From Novocure
Via Business Wire
NovoCure's Return On Capital Employed Overview
Via Benzinga
4 Analysts Have This to Say About NovoCure
Via Benzinga
Should You Buy Novocure Stock Right Now?
Most Wall Street analysts think this stock will skyrocket. They could be right. 
Via The Motley Fool
Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education
From Novocure
Via Business Wire
3 No-Brainer Stocks to Buy for Under $100 Right Now
These stocks might not remain under $100 for too much longer. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023
Via Benzinga
NovoCure (NVCR) Q1 2023 Earnings Call Transcript
NVCR earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Novocure Stock Dips As Q1 Earnings Miss Estimates, Higher Costs Hurt Bottom Line
Via Benzinga
NovoCure: Q1 Earnings Insights
Via Benzinga
What 4 Analyst Ratings Have To Say About NovoCure
Via Benzinga
2 Best Defensive Stocks to Buy in March
These two defensive stocks should shine in the event of a marketwide correction. 
Via The Motley Fool
Novocure Reports First Quarter 2023 Financial Results
From Novocure
Via Business Wire
The 3 Most Promising Healthcare Tech Stocks for April 2023
The best healthcare tech stocks provide investors with impressive upside potential, while promising to improve the healthcare sector. 
Via InvestorPlace
Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Novocure
Via Business Wire
Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023
From Novocure
Via Business Wire
NovoCure Earnings Perspective: Return On Capital Employed
Via Benzinga
Why NovoCure Stock Is Falling Today
Investors were looking for a stronger Q4 from the cancer company. 
Via The Motley Fool
Novocure to Report First Quarter 2023 Financial Results
From Novocure
Via Business Wire
Kristin Stafford Joins Novocure Board of Directors
From Novocure
Via Business Wire
Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
From Novocure
Via Business Wire
NovoCure (NVCR) Q4 2022 Earnings Call Transcript
NVCR earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023
Via Benzinga
2 Stocks That Could Rebound and Rise 30% or More in 2023
They're down, but they aren't yet out. 
Via The Motley Fool
Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
From Novocure
Via Business Wire
Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Allyson J. Ocean, M.D., Joins Novocure Board of Directors
From Novocure
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.